Innovative therapeutics

Investors/
Media

Welcome to BioMarin’s Investor Relations & Media Page

We’ve brought together a variety of information in one location to better assist you in your efforts to research and develop news articles and learn about our company.

BioMarin Pharmaceutical Inc. was founded in 1997, and since July 1999 the company's common stock has been traded on the Nasdaq National Market under the ticker symbol BMRN. BioMarin's policy is to fully comply with all rules put forth by the Securities and Exchange Commission and the Nasdaq National Market. For misplaced stock certificates, please contact our transfer agent directly.

Recent News
Feb 21, 2019

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2018 2017 % Change 2018 2017 % Change Total...

Feb 7, 2019

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that an ongoing open-label extension study treating patients with Brineura® (cerliponase alfa) continued to show a reduced rate of...

Feb 4, 2019

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in four platform and 10 poster presentations at the 15th Annual WORLDSymposiumTM being held February...

Events & Presentations

Stock Quote
NASDAQBMRN
BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information